Phase 3 Depression trials recruiting now

All Depression trials, every phase

Other phases for Depression

Phase 3 Depression trials

• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 30 locations
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 44 locations
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 51 locations
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 50 locations
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 179 locations
• A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
  NCT07716098 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 15 locations
• A Study of MI078 for Postpartum Depression
  NCT07721961 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · 36 locations
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
  NCT07573176 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 39 locations
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 69 locations
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 81 locations
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
  NCT07227454 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · 39 locations
• A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT07196501 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 60 locations
• A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
  NCT06958692 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode
  NCT03646058 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 9 locations
• Allopurinol in Depression
  NCT07574060 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 1 location
• Biomarker-guided rTMS for Treatment Resistant Depression
  NCT04041479 · Phase: Phase 3 · Ages: 22 Years to 65 Years · Sex: All (male and female) · 2 locations
• Brexpiprazole Treatment for Bipolar I Depression
  NCT04569448 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Cannabidiol for Bipolar Depression (CBD-BD)
  NCT05867849 · Phase: Phase 3 · Ages: 19 Years to 70 Years · Sex: All (male and female) · 6 locations
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
  NCT07484217 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 40 locations
• Cognitive Strategies in Early Psychosis 2
  NCT07263022 · Phase: Phase 3 · Ages: 18 Years to 35 Years · Sex: All (male and female) · 1 location
• Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
  NCT05474846 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Creatine for Depressed Male and Female Methamphetamine Users
  NCT02568878 · Phase: Phase 3 · Ages: 18 Years to 59 Years · Sex: All (male and female) · 1 location
• Dog Presence and Oxytocin on Trust Towards Therapists
  NCT06248710 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · 383 locations
• Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients
  NCT06508710 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 4 locations
• Effect of Probiotics "Psychobiotics" on Depression and Metabolic Syndrome in Saudi Arabia
  NCT06765057 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
  NCT07703722 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · 3 locations
• Efficacy of Chronotherapeutic Combination for Major Depressive Episode With Insomnia
  NCT07120880 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Efficacy of Statins Among Major Depressive Disorder
  NCT06698666 · Phase: Phase 3 · Ages: 20 Years to 45 Years · Sex: All (male and female) · 1 location
• Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33)
  NCT06273527 · Phase: Phase 2, Phase 3 · Ages: 21 Years to 55 Years · Sex: All (male and female) · 1 location
• Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
  NCT06830044 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 38 locations
• Evaluation of the Efficacy, Safety, and Tolerability of Lacosamide in Major Depressive Episodes of Bipolar Disorder Types I and II.
  NCT07412132 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Gut Microbiome Profiles in Patients with Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544).
  NCT06799351 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder
  NCT05644301 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 3 locations
• InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression
  NCT06781697 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
  NCT05603104 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Ketamine Augmentation of ECT in Treatment-Resistant Depression
  NCT07088380 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 106 locations
• Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
  NCT06529029 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Low Frequency Right Dorsolateral Pre Frontal Cortical Repetitive TMS for Bipolar Depression
  NCT06986460 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Lumateperone for Late-Life Depression
  NCT07623135 · Phase: Phase 3 · Ages: 60 Years and older · Sex: All (male and female) · 2 locations
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · 68 locations
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 39 locations
• NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06963021 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 35 locations
• Nebulized Ketamine for the Treatment of Major Depressive Disorder
  NCT06752759 · Phase: Phase 3 · Ages: 18 Years to 88 Years · Sex: All (male and female) · 1 location
• Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy
  NCT06706544 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
  NCT06713616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Perinatal Depression & Anxiety (PDA) and Maternal Gut Microbiome
  NCT06074250 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 43 Years · Sex: Female · 2 locations
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · 205 locations
• Prefrontal Glutamatergic Modulation by NAC and MBCT for Depression in Youth
  NCT07464886 · Phase: Phase 3 · Ages: 15 Years to 24 Years · Sex: All (male and female) · 1 location
• Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
  NCT07226232 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 5 locations
• REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
  NCT07280065 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
  NCT06860958 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 69 locations
• Study the Efficacy and Safety of the INtegral Cognitive REMediation Program (INCREM) for Depression
  NCT06590025 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06786624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 18 locations
• The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973786 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
  NCT05973851 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 12 locations
• The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
  NCT06247839 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
  NCT04984512 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location
• Understanding and Treating Suicidal Ideation With Ketamine
  NCT06891300 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · 1 location

Common questions

What does Phase 3 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.